Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
EMVision Medical Devices Ltd (EMV.AX)
AUD1.76
+0.24 (+15.41%)
AU ASX Healthcare Medical - Devices
Address
65 Epping Road 2113
Macquarie Park, NSW, AU
Macquarie Park, NSW, AU
CEO
Scott Philip Kirkland
Website
emvision.com.au
IPO
2018-12-12
ISIN AU0000028375
Description
EMVision Medical Devices Limited is an Australian enterprise specializing in the innovation, development, and market introduction of advanced imaging and diagnostic healthcare technologies. The company's principal offering is a compact, mobile brain scanner engineered for the swift detection and continuous tracking of strokes, in addition to fulfilling other medical imaging necessities. Founded in 2017, its operations are headquartered in Macquarie Park.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD1.76
+0.24 (+15.41%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
50.4K
Beta
1.03
Float Shares
62.54M
Free Float %
67.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.18% | +2.38% | -3.37% | -2.82% | -10.42% | -3.37% | +1.18% | +21.99% | -36.53% | +463.93% | +463.93% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1.76
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
15.24
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%-55.0% Q4'25: -100.0% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%-224.5% Q4'25: -3,078.6% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%-185.8%
-
EBIT margin Medical - Devices: +6.2%-175.1%
-
ROIC Medical - Devices: +3.3%-386.7% Q4'25: -307.6% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+6.2% Q4'25: +14.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.41× Q4'25: -0.13× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
1.70M
est: 2.10M (-19.1%)
|
4.36M
est: 4.10M (+6.4%)
|
6.97M
est: 12.40M (-43.8%)
|
11.22M
est: 7.60M (+47.6%)
|
5.05M
est: 4.50M (+12.3%)
|
5.50M
5.50M – 5.50M
+22.2% YoY
|
5.00M
5.00M – 5.00M
-9.1% YoY
|
8.50M
8.50M – 8.50M
+70.0% YoY
|
| EBITDA |
-9.56M
est: -1.93M (-394.2%)
|
-7.84M
est: -3.78M (-107.6%)
|
-5.99M
est: -11.42M (+47.5%)
|
-8.35M
est: -7.00M (-19.3%)
|
-8.71M
est: -4.14M (-110.2%)
|
-5.06M
-5.06M – -5.06M
-22.2% YoY
|
-4.60M
-4.60M – -4.60M
+9.1% YoY
|
-7.83M
-7.83M – -7.83M
-70.0% YoY
|
| EBIT |
-9.67M
est: -1.97M (-390.9%)
|
-8.08M
est: -3.85M (-110.1%)
|
-6.34M
est: -11.63M (+45.5%)
|
-2.26M
est: -7.13M (+68.3%)
|
-8.84M
est: -4.22M (-109.5%)
|
-5.16M
-5.16M – -5.16M
-22.2% YoY
|
-4.69M
-4.69M – -4.69M
+9.1% YoY
|
-7.97M
-7.97M – -7.97M
-70.0% YoY
|
| Net Income |
-8.40M
est: -5.64M (-48.9%)
|
-6.11M
est: -5.81M (-5.1%)
|
-3.87M
est: -1.28M (-202.0%)
|
-2.73M
est: -4.36M (+37.4%)
|
-9.81M
est: -8.03M (-22.1%)
|
-8.37M
-8.37M – -8.37M
-4.3% YoY
|
-9.66M
-9.66M – -9.66M
-15.3% YoY
|
-11.11M
-11.11M – -11.11M
-15.0% YoY
|
| SGA |
7.36M
est: 4.16M (+76.9%)
|
7.90M
est: 8.13M (-2.8%)
|
8.57M
est: 24.58M (-65.1%)
|
8.14M
est: 15.06M (-46.0%)
|
9.15M
est: 8.92M (+2.5%)
|
10.90M
10.90M – 10.90M
+22.2% YoY
|
9.91M
9.91M – 9.91M
-9.1% YoY
|
16.85M
16.85M – 16.85M
+70.0% YoY
|
| EPS |
-0.12
est: -0.07 (-81.8%)
|
-0.08
est: -0.07 (-19.4%)
|
-0.05
est: -0.02 (-232.0%)
|
-0.03
est: -0.05 (+33.5%)
|
-0.11
est: -0.09 (-17.0%)
|
-0.10
-0.10 – -0.10
-4.3% YoY
|
-0.11
-0.11 – -0.11
-15.3% YoY
|
-0.13
-0.13 – -0.13
-15.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-25 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-19.25M
OE per share TTM
-0.22
Owner's Yield
-12.55%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
11.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-192.3K
Shares Outstanding
92.94M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Scott Kirkland | Co-founder, Chief Executive Officer, MD & Executive Director | 526.7K | male |
| Emma Waldon | Company Secretary | — | female |
| Forough Khandan | Chief Technology Officer | — | female |
| Karl David Pechmann AGIA | Chief Financial Officer | — | male |
| Konstanty Bialkowski | Head of Tech Development | — | — |
| Robert Tiller | Head of Design | — | male |
| Christian Wight | Head of Regulatory, Quality & Clinical Operations | — | — |
| Stuart Crozier | Chief Scientific Officer | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EMV.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
